ATNT-08 CB-017: A PHASE 1/2 TRIAL OF BEVACIZUMAB PLUS TPI 287, A NOVEL BRAIN PENETRABLE ANTI-MICROTUBULE AGENT, IN PATIENTS WITH RECURRENT GLIOBLASTOMA NAÏVE TO ANTI-ANGIOGENIC THERAPY

Gardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Main Authors: Goldlust, Samuel, Nabors, L. Burt, Duic, J. Paul, Mohile, Nimish, Benkers, Tara, Hsu, Sigmund, Silberman, Sandra, Singer, Samuel, Farmer, George
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2015
Assuntos:
Abstracts from the 20th Annual Scientific Meeting of the Society for Neuro-Oncology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4638530/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nov205.08
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares